Bavarian Nordic A/S (OTCMKTS:BVNRY) Stock Price Passes Below 200-Day Moving Average - Should You Sell?

Bavarian Nordic A/S (OTCMKTS:BVNRY - Get Free Report) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $8.72 and traded as low as $7.60. Bavarian Nordic A/S shares last traded at $7.72, with a volume of 2,071 shares changing hands.

Bavarian Nordic A/S Price Performance

The company has a market cap of $1.83 billion, a price-to-earnings ratio of 11.23 and a beta of 1.55. The firm's fifty day moving average price is $7.65 and its 200-day moving average price is $8.67.

Bavarian Nordic A/S (OTCMKTS:BVNRY - Get Free Report) last announced its quarterly earnings data on Wednesday, March 5th. The company reported $0.47 EPS for the quarter, beating analysts' consensus estimates of $0.40 by $0.07. The firm had revenue of $299.48 million during the quarter, compared to analysts' expectations of $264.06 million. Bavarian Nordic A/S had a return on equity of 10.65% and a net margin of 18.33%. As a group, equities analysts forecast that Bavarian Nordic A/S will post 0.67 earnings per share for the current fiscal year.

About Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.